AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16255448 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (response burden) - instructions to complete both questionnaires irrespective of answers to the primary questionnaire.
Number of subjects: 4494
Study 12413994 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified urinary FSH
Number of subjects: 267
Study 12413994 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 267
Study 9440384 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional yogurt (125 g/d for 1 month)
Number of subjects: 39
Study 9440384 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented with yogurt cultures and Lactobacillus casei (YC) (125 g/d for 1 month)
Number of subjects: 39
Study 9440384 — intervention group
Group type: COMPARATOR
Intervention: Nonfermented gelled milk (125 g/d for 1 month)
Number of subjects: 39
Study 7602342 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m2 (arm A)
Number of subjects: 663
Study 7602342 — intervention group
Group type: EXPERIMENTAL
Intervention: CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) (arm B)
Number of subjects: 663
Study 7602342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 5 g/m2 plus doxorubicin 50 mg/m2 (arm C)
Number of subjects: 663
Study 7602342 — intervention group
Group type: COMPARATOR
Intervention: Comparison among all arms
Number of subjects: 663
Study 2196207 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat probe thermocoagulation
Number of subjects: 137
Study 345561 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-human thymocyte globulin (ATG)
Number of subjects: 0
Study 345561 — intervention group
Group type: COMPARATOR
Intervention: Steroids (control group)
Number of subjects: 0
Study 31843638 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNG Plus (substance use prevention and healthy nutrition)
Number of subjects: 1494
Study 31843638 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNG (substance use prevention only)
Number of subjects: 1494
Study 31843638 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (focusing on academic success)
Number of subjects: 1494
Study 31843638 — intervention group
Group type: EXPERIMENTAL
Intervention: Random subsample of 126 dyads (42 from each program)
Number of subjects: 1494
Study 29624549 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted transanal total mesorectal excision
Number of subjects: 49
Study 27804862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 27
Study 27804862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 25751578 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod, 7.5 mg bid orally
Number of subjects: 144
Study 25751578 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 144
Study 25751578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 24139191 — intervention group
Group type: EXPERIMENTAL
Intervention: BELIEF: Birth Emotions - Looking to Improve Expectant Fear (midwife-led psycho-education intervention)
Number of subjects: 0
Study 24139191 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 22009228 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 3
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fatty acids (FAs)
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA)
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios of SFAs/n‐3 PUFAs
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios of SFAs/n‐3 HUFAs
Number of subjects: 203
Study 18439088 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐6 PUFAs/n‐3 PUFAs
Number of subjects: 203
Study 17452162 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 837)
Number of subjects: 1669
Study 17452162 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 696) at doses >2.0 mg/kg
Number of subjects: 1669
Study 17452162 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 559) at doses >3.0 mg/kg
Number of subjects: 1669
Study 17452162 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 219) at doses >4.0 mg/kg
Number of subjects: 1669
Study 17452162 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 837) with a mean daily dose of 3.7 mg/kg (300 mg)
Number of subjects: 1669
Study 17452162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 832)
Number of subjects: 1669
Study 14620524 — intervention group
Group type: EXPERIMENTAL
Intervention: New paracetamol formulation with sodium bicarbonate
Number of subjects: 12
Study 14620524 — intervention group
Group type: COMPARATOR
Intervention: Conventional paracetamol formulation
Number of subjects: 12
Study 10632650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy (two single triple capsules containing 60 mg of bismuth subcitrate, 125 mg of tetracycline, and 125 mg of metronidazole) plus lansoprazole 30 mg b.d. for 7 days
Number of subjects: 66
Study 8938547 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (single subcutaneous dose)
Number of subjects: 40
Study 1384949 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 93
Study 1384949 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 93
Study 1384949 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD
Number of subjects: 93
Study 1384949 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertility and lower income (1 year before diagnosis)
Number of subjects: 93
Study 1384949 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors' reports of problems attributed to cancer
Number of subjects: 93
Study 3868934 — intervention group
Group type: EXPERIMENTAL
Intervention: 4'-epi-adriamycin (EPI) 50 mg/day for 6 days (regimen A)
Number of subjects: 37
Study 3868934 — intervention group
Group type: EXPERIMENTAL
Intervention: 4'-epi-adriamycin (EPI) 60 mg/day for 3 days X 2 courses with 4 days interval (regimen B)
Number of subjects: 37
Study 29727043 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Escherichia coli‐asparaginase (rASNase)
Number of subjects: 199
Study 29727043 — intervention group
Group type: COMPARATOR
Intervention: Native E.coli asparaginase (Asparaginase medac)
Number of subjects: 199
Study 29727043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 199
Study 27827284 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 23
Study 27827284 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 23
Study 24928586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 262
Study 23206463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general/epidural anaesthesia
Number of subjects: 61
Study 23206463 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone (control group)
Number of subjects: 61
Study 23206463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 20591171 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) intervention using a combination of three videotaped visits and five telephone calls, an in-home messaging device, and additional telephonic contact as needed over a 3-month study period
Number of subjects: 50
Study 20591171 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 50
Study 17570803 — intervention group
Group type: EXPERIMENTAL
Intervention: Eighth grade level message
Number of subjects: 519
Study 17570803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninth grade level message
Number of subjects: 519
Study 17570803 — intervention group
Group type: EXPERIMENTAL
Intervention: First year college level message
Number of subjects: 519
Study 16340286 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tonsillectomy
Number of subjects: 197
Study 16340286 — intervention group
Group type: COMPARATOR
Intervention: Unilateral tonsillectomy
Number of subjects: 197
Study 12632661 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 46
Study 12632661 — intervention group
Group type: COMPARATOR
Intervention: Healthy blood donors (control group)
Number of subjects: 46
Study 10337455 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtol standardized (MYS, Gelomyrtol forte, 3 x 300 mg)
Number of subjects: 246
Study 10337455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 10337455 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtol standardized (MYS)
Number of subjects: 246
Study 7789631 — intervention group
Group type: EXPERIMENTAL
Intervention: doxazosin
Number of subjects: 30
Study 7789631 — intervention group
Group type: COMPARATOR
Intervention: captopril
Number of subjects: 30
Study 7789631 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 30
Study 1819779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular beta-interferon (3 x 10(6) IU for 10 consecutive days)
Number of subjects: 94
Study 1819779 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscular injections
Number of subjects: 94
Study 7146040 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release preparation of ferrous glycine sulphate ('Ferrocontin' Continus)
Number of subjects: 40
Study 7146040 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate
Number of subjects: 40
Study 30117784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored ACT mobile app (n=17)
Number of subjects: 39
Study 30117784 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored ACT mobile app (n=22)
Number of subjects: 39
Study 28743662 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life conversation card game
Number of subjects: 93
Study 26090580 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Intervention (YI)
Number of subjects: 76
Study 26090580 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Dance Control (DC)
Number of subjects: 76
Study 26090580 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 76
Study 25028457 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (7-year randomized, double-blind, placebo-controlled trial)
Number of subjects: 13590
Study 25028457 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger sites and/or sites that received retention and adherence grants
Number of subjects: 13590
Study 20882342 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% Jatropha curcas seed meal (JCSM)
Number of subjects: 30
Study 20882342 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Jatropha curcas seed meal (JCSM)
Number of subjects: 30
Study 20882342 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% Jatropha curcas seed meal (JCSM)
Number of subjects: 30
Study 20882342 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Jatropha curcas seed meal (JCSM)
Number of subjects: 30
Study 20882342 — intervention group
Group type: COMPARATOR
Intervention: Control group (soya bean meal 20%)
Number of subjects: 30
Study 19412944 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 1000000
Study 19412944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 1000000
Study 19412944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000000
Study 17470864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg IV every 2 weeks and erlotinib 150 mg orally daily
Number of subjects: 51
Study 15370671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 180
Study 15370671 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 180
Study 15370671 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discontinuation of antibiotic therapy in FUO patients
Number of subjects: 180
Study 11358776 — intervention group
Group type: EXPERIMENTAL
Intervention: What Should I Do? booklet
Number of subjects: 4878
Study 11358776 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Care Manual booklet
Number of subjects: 4878
Study 11358776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 4878
Study 7836016 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seropositive group
Number of subjects: 40000
Study 7836016 — intervention group
Group type: COMPARATOR
Intervention: HIV seronegative group
Number of subjects: 40000
Study 3221960 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks
Number of subjects: 139
Study 3221960 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks + CCNU in one dose of 100 mg/m repeated at intervals of 6‐8 weeks
Number of subjects: 139
Study 29068044 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonothrombolysis (CEST)
Number of subjects: 83
Study 29068044 — intervention group
Group type: COMPARATOR
Intervention: Sham CEST
Number of subjects: 83
Study 26936093 — intervention group
Group type: EXPERIMENTAL
Intervention: High nCPAP at 7 cm of water
Number of subjects: 271
Study 26936093 — intervention group
Group type: COMPARATOR
Intervention: Standard nCPAP at 5 cm of water
Number of subjects: 271
Study 26432320 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE/C (rapid palatal expansion and constriction) for 7 weeks
Number of subjects: 44
Study 26432320 — intervention group
Group type: COMPARATOR
Intervention: RPE (rapid palatal expansion) for 1 week
Number of subjects: 44
Study 23601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (Group IVM)
Number of subjects: 60
Study 23601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (Group EM)
Number of subjects: 60
Study 23601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine-bupivacaine (Group EMB)
Number of subjects: 60
Study 23601264 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine-ropivacaine (Group EMR)
Number of subjects: 60
Study 23601264 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 21397260 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adverse event reporting system (period 1)
Number of subjects: 2
Study 21397260 — intervention group
Group type: COMPARATOR
Intervention: New adverse event reporting system focusing on 6 sentinel events (period 2)
Number of subjects: 2
Study 21397260 — intervention group
Group type: EXPERIMENTAL
Intervention: New adverse event reporting system (period 2)
Number of subjects: 2
Study 18300930 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of the ankle dorsiflexors and quadriceps for 2 weeks of neuromuscular electrical stimulation followed by 8 weeks of FES used at home and school
Number of subjects: 14
Study 18300930 — intervention group
Group type: COMPARATOR
Intervention: Control group continued with usual physiotherapy program
Number of subjects: 14
Study 16511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 16511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 16511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 16511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 16511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 16511729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 12662230 — intervention group
Group type: EXPERIMENTAL
Intervention: Same size dressing (SSD)
Number of subjects: 0
Study 12662230 — intervention group
Group type: COMPARATOR
Intervention: Double size dressing (DSD)
Number of subjects: 0
Study 11152032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 1/400000 adrenaline (n=8)
Number of subjects: 15
Study 11152032 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 0.25% (n=7)
Number of subjects: 15
Study 9624783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 500 mg once daily for 7 days
Number of subjects: 272
Study 9624783 — intervention group
Group type: COMPARATOR
Intervention: Oral ciprofloxacin 500 mg twice daily for 10 days
Number of subjects: 272
Study 7837834 — intervention group
Group type: EXPERIMENTAL
Intervention: Zemide 20 (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Number of subjects: 12
Study 7837834 — intervention group
Group type: COMPARATOR
Intervention: Commercially available tablet formulation (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Number of subjects: 12
Study 3341391 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg per day)
Number of subjects: 47
Study 3341391 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg per day)
Number of subjects: 47
Study 31424957 — intervention group
Group type: EXPERIMENTAL
Intervention: TUNEL
Number of subjects: 50
Study 31424957 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNA
Number of subjects: 50
Study 31424957 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX2
Number of subjects: 50
Study 31424957 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptosis rates
Number of subjects: 50
Study 31424957 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferation rates
Number of subjects: 50
Study 31075683 — intervention group
Group type: EXPERIMENTAL
Intervention: Early MS group (N = 24)
Number of subjects: 69
Study 31075683 — intervention group
Group type: EXPERIMENTAL
Intervention: Late MS group (N = 45)
Number of subjects: 69
Study 27777128 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning about Activity and Understanding Nutrition for Child Health (LAUNCH)
Number of subjects: 0
Study 27777128 — intervention group
Group type: COMPARATOR
Intervention: Motivational-interviewing intervention (MI)
Number of subjects: 0
Study 27777128 — intervention group
Group type: COMPARATOR
Intervention: Standard care (STC)
Number of subjects: 0
Study 26814847 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF based therapy in predictor positive (P+) group
Number of subjects: 167
Study 26814847 — intervention group
Group type: COMPARATOR
Intervention: TwHF based therapy in predictor negative (P-) group
Number of subjects: 167
Study 26814847 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and Sulfasalazine combination therapy (M) in predictor positive (P+) group
Number of subjects: 167
Study 26814847 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and Sulfasalazine combination therapy (M) in predictor negative (P-) group
Number of subjects: 167
Study 23754758 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 1 (3% mortality and MI)
Number of subjects: 320
Study 23754758 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 4 (14% mortality and MI)
Number of subjects: 320
Study 23754758 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 1 (1% cardiovascular death and MI)
Number of subjects: 320
Study 23754758 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP quartile 4 (11% cardiovascular death and MI)
Number of subjects: 320
Study 21472664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 48
Study 21472664 — intervention group
Group type: COMPARATOR
Intervention: Colestimide
Number of subjects: 48
Study 19246522 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled patients at the lead site (n = 27)
Number of subjects: 97
Study 19246522 — intervention group
Group type: COMPARATOR
Intervention: Eligible nonenrolled patients at the lead site (n = 70)
Number of subjects: 97
Study 16978844 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus probiotic food (250 mL of yogurt containing Bifidobacterium animalis and Lactobacillus casei at 10^7 CFU/mL) for 1 week and administered for 3 months
Number of subjects: 65
Study 16978844 — intervention group
Group type: COMPARATOR
Intervention: Milk placebo
Number of subjects: 65
Study 15343566 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 106
Study 15343566 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty plus cilostazol (200 mg/day for 6 months)
Number of subjects: 106
Study 10937764 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (320 mg I/ml)
Number of subjects: 119
Study 10937764 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (350 mg I/ml)
Number of subjects: 119
Study 9080918 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (n = 132)
Number of subjects: 902
Study 9080918 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorthalidone (n = 126)
Number of subjects: 902
Study 9080918 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine maleate (n = 131)
Number of subjects: 902
Study 9080918 — intervention group
Group type: EXPERIMENTAL
Intervention: doxazosin mesylate (n = 134)
Number of subjects: 902
Study 9080918 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril maleate (n = 135)
Number of subjects: 902
Study 9080918 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 234)
Number of subjects: 902
Study 7920926 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF with transfer on day 6
Number of subjects: 0
Study 7920926 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfers of frozen-thawed blastocysts
Number of subjects: 0
Study 7920926 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture
Number of subjects: 0
Study 30896297 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Catastrophizing Scale (ICS) - nighttime catastrophizing subscale (11 items)
Number of subjects: 1615